MME and myocardial infarction: The ongoing PARADISE-AMI trial is evaluating the safety and efficacy of angiotensin receptor II blocker-neprilysin inhibitors (ARNIs) compared with ramipril in addition to standard post myocardial infarction (MI) pharmacotherapy [8].